Global Methenamine Hippurate Tablets Market – Industry Trends and Forecast to 2030

Global Methenamine Hippurate Tablets Market, By Type (20 Tablets/Bottle, 6 Tablets/ Bottle), Application (Uncomplicated UTIs, Healthcare-associated UTIs), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Methenamine Hippurate Tablets Market Analysis and Size

As the incidence of urinary tract infections is growing globally with reported cases of 50-60% in adult women, the demand of methenamine hippurate tablets and therefore anticipated to provide market with the huge growth. Furthermore, growing government support for APIs development and rising investment in pharmaceutical industries also expand the market growth.

Data Bridge Market Research analyses a growth rate in the methenamine hippurate tablets market in the forecast period 2023-2030. The expected CAGR of the methenamine hippurate tablets market tends to be around 6.50% in the mentioned forecast period. The market was valued at USD 8.9 billion in 2022, and it would grow up to USD 14.73 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Methenamine Hippurate Tablets Market Scope and Segmentation

Market Definition

Methenamine hippurate tablets are the type of antiseptic drugs which is indicated for urinary tract infections. Methenamine hippurate tablets are manufactured by mixing some other compounds, including povidone, magnesium stearate, and saccharin sodium. This tablet has been reported to get readily absorbed by the gastrointestinal tract and thus effectively distributed in the body fluid. A single dose of methenamine hippurate tablets has been recorded to show antibacterial activity after half an hour of single 1g dose administration. From the overall tablet methenamine moiety excreted out with urine however the hippurate

Methenamine Hippurate Tablets Market Dynamics

Drivers

• Availability of Different Dosage Forms

The extensive availability of different dosage forms are enhancing the growth of the market. 20 Tablets/Bottle is a type of Hydroxycut, which contains a mixture of Amide and Carboxylic Acid salts. It is soluble in water and ethanol. Then there is another form called 60 Tablets/Bottle, a form of methenamine hippurate. It is used to treat horses having chronic diarrhea and is as an anti-carrhythmic drug in humans. It is a very effective anti-carrhythmic drug available today it contains approximately 1 mg of the active ingredient. Then , a bottle is a type of container with a neck that is narrower than the body. Bottles are often made of glass, plastic, and ceramic. Thus, all these different availability is boosting the growth of the market.

Opportunities

• Rising Cases of Urinary Tract Infections

Community-associated UTI (CAUTI) incidence is 0.7% and the primary risk factors are age, history of UTI, sexual activity and diabetes. Globally, around 150 million individuals develop UTIs. The highest incidence of symptomatic infections is prevalent in young, sexually active women aged 18 to 24 years, with one-third to one-half of women reported having at least one UTI by age 32. In the U.S., 70–80% of complicated UTIs are attributable to catheters, resulting in 1 million cases per year. Thus, this boosts the market growth.

 Restraints/Challenges

• Severe Effects of Methenamine Hippurate Tablets

The common symptoms associated with methenamine hippurate tablets are nausea, diarrhea, abdominal cramps, vomiting, and loss of appetite. If any of these effects continue or get worsen, immediate consultation is necessary. Painful or difficult urination may occur with methenamine, although less often.

This methenamine hippurate tablets market market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the methenamine hippurate tablets market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Global Methenamine Hippurate Tablets Market Scope

The methenamine hippurate tablets market is segmented on the basis of type, application, population type, end user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• 20 Tablets/Bottle
• 6 Tablets/ Bottle

Application

• Uncomplicated UTIs
• Healthcare-associated UTIs

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Methenamine Hippurate Tablets Market Regional Analysis/Insights

The methenamine hippurate tablets market is analyzed and market size insights and trends are provided by type, application, end user, distribution channel as referenced above.

The major countries covered in the methenamine hippurate tablets market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Europe has been witnessing the highest growth for the methenamine hippurate tablets market throughout the forecasted period because of the constant rise in the chronic infections among women and growing cases of postmenopausal UTIs.

North America dominates the market because of the growing disposable income and increasing cases of urological procedures. Furthermore, Europe accounts the second largest market share because of the rising awareness for urinary tract infections and wide presence of distribution network for methenamine hippurate tablets.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Methenamine Hippurate Tablets Market Share Analysis

The methenamine hippurate tablets market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to methenamine hippurate tablets market.

Key players operating in the methenamine hippurate tablets market include:

• Validus Pharmaceuticals LLC (U.S.)
• Alvogen (U.S.)
• Micro Labs USA, Inc. (India)
• Aurobindo Pharma USA. (U.S.)
• Edenbridge Pharmaceuticals, LLC (U.S.)
• Kreative Organics (India)
• Viatris Inc (U.S.)
• CorePharma LLC (U.S.)